<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02965859</url>
  </required_header>
  <id_info>
    <org_study_id>PNA-20140110-v2</org_study_id>
    <nct_id>NCT02965859</nct_id>
  </id_info>
  <brief_title>The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B</brief_title>
  <official_title>A Randomized,Double-blind,Double-dummy,Multiple-dose Parallel Control,Multiple Centers Study to Assess the Safety and Dose-range of Metacavir Enteric-coated Capsules for Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Yipinhong Pharmaceutical CO.,LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Yipinhong Pharmaceutical CO.,LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to evaluate the safety and effectiveness of different doses of
      Metacavir Enteric-coated Capsules in treatment of chronic hepatitis B,as well as to find an
      appropriate clinical dosage by comparing the effect of different doses of treatment,in order
      to provide references of clinical trial of the next phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      180 eligible subjects will be included.According to the set grouping method of dose
      escalation.Subjects will be randomized in a 1:1:1:1 proportion of Metacavir Enteric-coated
      Capsules(80mg/160mg/320mg) group,positive control group or placebo control group.Each group
      has 36 subjects.

      1.Subjects will use the study medication(2 hours before or after meal,once a day) from Visit
      3 to Visit 5.

        1. Metacavir Enteric-coated Capsules 80mg Group:Metacavir Enteric-coated Capsules
           80mg,Metacavir Enteric-coated Capsules Placebo 240mg,Adefovir Dipivoxil Capsule Placebo
           10mg;

        2. Metacavir Enteric-coated Capsules 160mg Group:Metacavir Enteric-coated Capsules
           160mg,Metacavir Enteric-coated Capsules Placebo 160mg,Adefovir Dipivoxil Capsule Placebo
           10mg;

        3. Metacavir Enteric-coated Capsules 320mg Group:Metacavir Enteric-coated Capsules
           320mg,Adefovir Dipivoxil Capsule Placebo 10mg;

        4. Positive Control(Adefovir Dipivoxil Capsule) Group:Metacavir Enteric-coated Capsules
           Placebo 320mg,Adefovir Dipivoxil Capsule 10mg;

        5. Placebo Control Group:Metacavir Enteric-coated Capsules Placebo 320mg,Adefovir Dipivoxil
           Capsule Placebo 10mg;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline in the logarithms of measurement data of HBV-DNA at Week 12 of treatment.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change from baseline in the logarithms of measurement data of HBV-DNA at Week 12 of treatment.（Unit：log10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-chronic hepatitis B</measure>
    <time_frame>12 weeks</time_frame>
    <description>The proportion of subjects whose HBV-DNA are down to double logarithms at Week 12 of treatment.(Unit：%)
The proportion of subjects whose HBV-DNA are not detected or less than upper limit of normal at Week 12 of treatment.(Unit：%)
The proportion of subjects (HBeAg positive at baseline) whose is changed at Week 12 of treatment.(Unit：%)
The proportion of subjects whose HBsAg is changed to negative at Week 12 of treatment.(Unit：%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events(AEs)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Metacavir Enteric-coated Capsule 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metacavir Enteric-coated Capsules 80mg
Metacavir Enteric-coated Capsules Placebo 240mg
Adefovir Dipivoxil Capsule Placebo 10mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metacavir Enteric-coated Capsules 160mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metacavir Enteric-coated Capsules 160mg
Metacavir Enteric-coated Capsules Placebo 160mg
Adefovir Dipivoxil Capsule Placebo 10mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metacavir Enteric-coated Capsules 320mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Metacavir Enteric-coated Capsules 320mg
Adefovir Dipivoxil Capsule Placebo 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adefovir Dipivoxil Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metacavir Enteric-coated Capsules Placebo 320mg
Adefovir Dipivoxil Capsule 10mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Metacavir Enteric-coated Capsules Placebo 320mg
Adefovir Dipivoxil Capsule Placebo 10mg;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metacavir Enteric-coated Capsules 80mg</intervention_name>
    <description>Metacavir Enteric-coated Capsules 80mg</description>
    <arm_group_label>Metacavir Enteric-coated Capsule 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metacavir Enteric-coated Capsules 160mg</intervention_name>
    <description>Metacavir Enteric-coated Capsules 160mg</description>
    <arm_group_label>Metacavir Enteric-coated Capsules 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metacavir Enteric-coated Capsules 320mg</intervention_name>
    <description>Metacavir Enteric-coated Capsules 320mg</description>
    <arm_group_label>Metacavir Enteric-coated Capsules 320mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metacavir Enteric-coated Capsules Placebo 240mg</intervention_name>
    <description>Metacavir Enteric-coated Capsules Placebo 240mg</description>
    <arm_group_label>Metacavir Enteric-coated Capsule 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metacavir Enteric-coated Capsules Placebo 160mg</intervention_name>
    <description>Metacavir Enteric-coated Capsules Placebo 160mg</description>
    <arm_group_label>Metacavir Enteric-coated Capsules 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metacavir Enteric-coated Capsules Placebo 320mg</intervention_name>
    <description>Metacavir Enteric-coated Capsules Placebo 320mg</description>
    <arm_group_label>Adefovir Dipivoxil Capsule</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir Dipivoxil Capsule10mg</intervention_name>
    <description>Adefovir Dipivoxil Capsule10mg</description>
    <arm_group_label>Adefovir Dipivoxil Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir Dipivoxil Capsule Placebo 10mg</intervention_name>
    <description>Adefovir Dipivoxil Capsule Placebo 10mg</description>
    <arm_group_label>Metacavir Enteric-coated Capsule 80mg</arm_group_label>
    <arm_group_label>Metacavir Enteric-coated Capsules 160mg</arm_group_label>
    <arm_group_label>Metacavir Enteric-coated Capsules 320mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are at least 18 years of age and no older than 65;

          -  Subjects,with an established clinical history of HBV at Screening,has a positive HBsAg
             test(&gt;6months) regardless of a positive/negative HBeAg test;

          -  At Screening,HBV-DNA&gt;10^5 copies/ml in HBeAg positive or HBV-DNA&gt;10^4 copies/ml in
             HBeAg negative(HBV-DNA was evaluated by polymerase chain reaction fluorescent
             labeling.);

          -  Subjects with abnormal liver function test defined as alanine aminotransferase(ALT)
             was 2~10 times upper limit of normal in HBeAg positive or 1.5~10 times upper limit of
             normal in HBeAg negative;

          -  Subjects who are willing to require any other treatment for anti-hepatitis B during
             the study period;

          -  Subjects who are willing to take measures for effective non-pharmaceutical
             contraception;

          -  Given their signed written informed consent to participate;

        Exclusion Criteria:

          -  Subjects with hepatitis C(HCV),hepatitis D(HDV),autoimmune hepatitis,hereditary liver
             disease or any other active hepatitis;

          -  A positive human immunodeficiency virus(HIV) test result;

          -  Subjects,who in the opinion of the investigator,have a current diagnosis of
             hepatocellular carcinoma or serum α-fetoprotein(AFP)&gt;100ug/L;

          -  Subjects with severe hepatitis or decompensated liver disease defined as hepatic
             encephalopathy,ascites,low protein blood syndrome(albumin ≤30g/l) or variceal
             bleeding;

          -  Serum Creatinine(SCr) exceeds upper limit of normal;

          -  At Screening,ALT&gt;10 times upper limit of normal,Total Bilirubin(TBIL)&gt;double upper
             limit of normal or transient hepatic decompensation caused by condition aggravation;

          -  Subjects who required treatment with nucleoside antiviral drugs such as
             lamivudine,Adefovir dipivoxil,Telbivudine,Tenofovir disoproxil or Entecavir before
             Screening;

          -  Subjects who require treatment with interferon-α，thymosin α-1 or other antiviral
             therapy,immunosuppressive agents,immune modulators within 6 months before Screening;

          -  Subjects with cardiac disease,hematological system disease,cancer,impaired immunity or
             psychiatric disease;

          -  Hemoglobin&lt;10g/dl,white blood cell count&lt;3.5 10^9/L,platelets&lt;80 10^9/L;

          -  Subjects,who in the opinion of the investigator,have a current diagnosis of
             pancreatitis pre-dose within 24 weeks;

          -  History of hypersensitivity or allergy to any of the study drugs;

          -  Subjects who participate in other clinical trials within 3 months prior to Screening;

          -  Women who are pregnant or lactating or planning a pregnancy recently;

          -  Subjects in the opinion of the investigator,could not participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maorong Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>81 Military Hospital of China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yonggang Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing 302 Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongfeng Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Hospital of Nanjing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yanlin Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wannan Medical College Yijishan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maorong Wang</last_name>
    <phone>025-80864021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>81 Military Hospital of China</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maorong Wang</last_name>
      <phone>025-80864021</phone>
    </contact>
    <investigator>
      <last_name>Maorong Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

